Protein S as a therapeutic target.

Area of Science:

• Biochemistry
• Hematology
• Molecular Biology

Background:

• Protein S (PS) is a vital anticoagulant protein.
• PS also plays a role in cell signaling via Tyro3-Axl-MerTK receptors.
• Dysregulation of PS activity is linked to severe bleeding and thrombotic conditions.

Purpose of the Study:

• To explore therapeutic strategies targeting Protein S activity.
• To evaluate methods for enhancing or inhibiting PS function for clinical benefit.
• To investigate the broader therapeutic potential of PS beyond coagulation.

Main Methods:

• Development of PS-targeting nanobodies and monoclonal antibodies.
• Application of RNA interference (RNAi) for PS modulation.
• Preclinical testing in murine models and Phase 1/2 clinical trials.

Main Results:

• A PS-enhancing nanobody showed significant antithrombotic effects in mice.
• PS inhibitors (monoclonal antibodies, siRNAs) demonstrated safety and efficacy in preclinical studies.
• A PS-targeting monoclonal antibody showed preliminary safety and efficacy in Von Willebrand disease patients.

Conclusions:

• Targeting Protein S activity presents a viable therapeutic approach for thrombotic and bleeding disorders.
• PS modulation offers potential for managing conditions like disseminated intravascular coagulation, purpura fulminans, and venous thromboembolism.
• PS-targeted therapies may also mitigate tissue damage through its receptor signaling pathways.